Trisomy 14 with thrombocytosis and monocytosis.
It has been reported that trisomy 14 is associated with myeloid malignancies, but a case with increased platelet count has also been reported. However, the clinical significance of trisomy 14 is still uncertain. We report a patient with trisomy 14 with thrombocytosis and a gradual increase in monocytosis. He was treated with hydroxyurea, cytarabine and aclarubicin in low doses and his quality of life was maintained for a period of about 1 year from blastic crisis. Hydroxyurea, cytarabine or aclarubicin in low doses may be the treatment of choice for trisomy 14 patients with respect to the patients' quality of life.
Kaya
H
H
Department of Internal Medicine, Fukui-ken Saiseikai Hospital, Fukui, Japan.
Nakamura
S
S
Okafuji
K
K
Terasaki
Y
Y
Maeno
K
K
Tanaka
N
N
Ohtake
S
S
Matsuda
T
T
D015250:Aclarubicin / Q000008:administration & dosage; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002883:Chromosomes, Human, Pair 14; D003561:Cytarabine / Q000008:administration & dosage; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D015477:Leukemia, Myelomonocytic, Chronic / Q000150:complications / Q000188:drug therapy / Q000235:genetics; D007960:Leukocyte Disorders / Q000188:drug therapy / Q000235:genetics; D008297:Male; D009000:Monocytes; D011788:Quality of Life; D013922:Thrombocytosis / Q000188:drug therapy / Q000209:etiology / Q000235:genetics*; D014314:Trisomy / Q000235:genetics / Q000473:pathology*
D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D003561:Cytarabine; D015250:Aclarubicin; D006918:Hydroxyurea